aTyr Pharma’s Innovative Fibrosis Treatment and Promising Pipeline Garner Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on aTyr Pharma (ATYR – Research Report), retaining the price target of $35.00.

Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the potential of aTyr Pharma’s innovative approach to treating fibrosis. The company’s preclinical candidate, ATYR0101, has shown promise in reversing fibrosis by targeting myofibroblasts, which are crucial in the progression of this condition. This novel mechanism of action, derived from a proprietary domain of aspartyl-tRNA synthetase, could represent a significant advancement in treating pulmonary fibrosis, a disease with limited current treatment options.
Additionally, the anticipated filing of an Investigational New Drug (IND) application for ATYR0101 in the second half of 2026 adds to the company’s robust development pipeline. This pipeline is further strengthened by the ongoing pivotal Phase 3 studies of efzofitimod for interstitial lung disease. With critical Phase 3 data expected within six months, aTyr Pharma is positioned to attract significant investor attention, reinforcing Pantginis’s positive outlook and Buy rating.

In another report released on May 8, Leerink Partners also reiterated a Buy rating on the stock with a $16.00 price target.